IL249406A0 - The history of indane and indoline and their use as soluble guanylate cyclase inhibitors - Google Patents

The history of indane and indoline and their use as soluble guanylate cyclase inhibitors

Info

Publication number
IL249406A0
IL249406A0 IL249406A IL24940616A IL249406A0 IL 249406 A0 IL249406 A0 IL 249406A0 IL 249406 A IL249406 A IL 249406A IL 24940616 A IL24940616 A IL 24940616A IL 249406 A0 IL249406 A0 IL 249406A0
Authority
IL
Israel
Prior art keywords
indane
guanylate cyclase
soluble guanylate
indoline derivatives
cyclase activators
Prior art date
Application number
IL249406A
Other languages
English (en)
Hebrew (he)
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of IL249406A0 publication Critical patent/IL249406A0/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4465—Non condensed piperidines, e.g. piperocaine only substituted in position 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL249406A 2014-07-02 2016-12-06 The history of indane and indoline and their use as soluble guanylate cyclase inhibitors IL249406A0 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462020166P 2014-07-02 2014-07-02
US201562168627P 2015-05-29 2015-05-29
PCT/IB2015/055006 WO2016001875A1 (en) 2014-07-02 2015-07-02 Indane and indoline derivatives and the use thereof as soluble guanylate cyclase activators

Publications (1)

Publication Number Publication Date
IL249406A0 true IL249406A0 (en) 2017-02-28

Family

ID=53724402

Family Applications (1)

Application Number Title Priority Date Filing Date
IL249406A IL249406A0 (en) 2014-07-02 2016-12-06 The history of indane and indoline and their use as soluble guanylate cyclase inhibitors

Country Status (26)

Country Link
US (2) US10208018B2 (Direct)
EP (1) EP3164395B1 (Direct)
JP (1) JP2017519835A (Direct)
KR (1) KR20170021345A (Direct)
CN (1) CN106470985A (Direct)
AP (1) AP2016009609A0 (Direct)
AU (1) AU2015283617B2 (Direct)
BR (1) BR112016030733A2 (Direct)
CA (1) CA2953885A1 (Direct)
CL (1) CL2016003329A1 (Direct)
CO (1) CO2017000222A2 (Direct)
CR (1) CR20170003A (Direct)
CU (1) CU20160192A7 (Direct)
EA (1) EA030634B1 (Direct)
EC (1) ECSP17007208A (Direct)
ES (1) ES2732758T3 (Direct)
GT (1) GT201600269A (Direct)
IL (1) IL249406A0 (Direct)
MX (1) MX2016017325A (Direct)
PE (1) PE20170323A1 (Direct)
PH (1) PH12016502539A1 (Direct)
SG (1) SG11201610226SA (Direct)
SV (1) SV2016005351A (Direct)
TN (1) TN2016000556A1 (Direct)
TW (1) TW201625584A (Direct)
WO (1) WO2016001875A1 (Direct)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201625584A (zh) 2014-07-02 2016-07-16 諾華公司 茚滿及吲哚啉衍生物及其作為可溶性鳥苷酸環化酶活化劑之用途
JP2018529745A (ja) 2015-10-06 2018-10-11 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ Ｎｒｆ２レギュレーターとしてのビアリールピラゾール
AU2016370806A1 (en) * 2015-12-18 2018-07-05 Novartis Ag Indane derivatives and the use thereof as soluble guanylate cyclase activators
WO2017201683A1 (en) 2016-05-25 2017-11-30 Merck Sharp & Dohme Corp. Substituted tetrahydroisoquinoline compounds useful as gpr120 agonists
US10682323B2 (en) 2016-07-22 2020-06-16 Toa Eiyo Ltd. Therapeutic agent for glaucoma
WO2018069148A1 (de) 2016-10-11 2018-04-19 Bayer Pharma Aktiengesellschaft Kombination enthaltend sgc aktivatoren und mineralocorticoid-rezeptor-antagonisten
WO2019081456A1 (en) 2017-10-24 2019-05-02 Bayer Aktiengesellschaft USE OF SGC ACTIVATORS AND STIMULATORS COMPRISING A BETA2 SUBUNIT
EP3498298A1 (en) 2017-12-15 2019-06-19 Bayer AG The use of sgc stimulators and sgc activators alone or in combination with pde5 inhibitors for the treatment of bone disorders including osteogenesis imperfecta (oi)
CN112055584A (zh) 2018-04-30 2020-12-08 拜耳公司 sGC活化剂和sGC刺激剂用于治疗认知障碍的用途
BR112020022340A2 (pt) 2018-05-15 2021-02-02 Bayer Aktiengesellschaft benzamidas substituídas por 1,3-tiazol-2-il para o tratamento de doenças associadas com sensibilização de fibras nervosas
EP3574905A1 (en) 2018-05-30 2019-12-04 Adverio Pharma GmbH Method of identifying a subgroup of patients suffering from dcssc which benefits from a treatment with sgc stimulators and sgc activators in a higher degree than a control group
WO2020030489A1 (en) 2018-08-06 2020-02-13 Nicox S.A. Nitric oxide releasing phosphodiesterase type 5 inhibitor
WO2020148379A1 (en) 2019-01-17 2020-07-23 Bayer Aktiengesellschaft Methods to determine whether a subject is suitable of being treated with an agonist of soluble guanylyl cyclase (sgc)
TW202412753A (zh) 2022-06-09 2024-04-01 德商拜耳廠股份有限公司 用於治療女性心臟衰竭合併保留射出分率的可溶性鳥苷酸環化酶活化劑

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU228111B1 (en) 1998-07-08 2012-11-28 Sanofi Aventis Deutschland Sulfur substituted sulfonylaminocarboxylic acid n-arylamides, their preparation, their use and pharmaceutical preparations comprising them
EP1420023B1 (en) 2001-01-24 2006-12-06 Yung Shin Pharmaceutical Ind. Co., Ltd. Use of fused pyrazolyl compounds for the preparation of a medicament for treating hypertension
DE10110749A1 (de) 2001-03-07 2002-09-12 Bayer Ag Substituierte Aminodicarbonsäurederivate
DE10110750A1 (de) 2001-03-07 2002-09-12 Bayer Ag Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften
WO2004078163A2 (en) 2003-02-28 2004-09-16 Transform Pharmaceuticals, Inc. Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen
DE10216145A1 (de) 2002-04-12 2003-10-23 Bayer Ag Verwendung von Stimulatoren der löslichen Guanylatcyclase zur Behandlung von Glaukom
CN101626688A (zh) * 2006-12-11 2010-01-13 雷维瓦药品公司 茚满酮基胆碱酯酶抑制剂的组合物、合成和使用方法
DE102007015035A1 (de) 2007-03-29 2008-10-02 Bayer Healthcare Ag Substituierte Dibenzoesäure-Derivate und ihre Verwendung
CA2697678C (en) 2007-08-31 2015-06-23 Kalsi Engineering, Inc. Rotary seal with improved film distribution
BRPI0816382A2 (pt) * 2007-09-06 2015-02-24 Merck Sharp & Dohme Composto, composição, e, métodos para ativar a guanilato ciclase solúvel e para tratar ou previnir doenças
WO2009068652A1 (en) 2007-11-30 2009-06-04 Smithkline Beecham Corporation 2, 6-disubstituted pyridines and 2, 4-disubstituted pyrimidines as soluble guanylate cyclase activators
WO2009071504A1 (en) 2007-12-03 2009-06-11 Smithkline Beecham Corporation 2,6-disubstituted pyridines as soluble guanylate cyclase activators
CA2720343A1 (en) 2008-04-04 2009-10-08 Takeda Pharmaceutical Company Limited Heterocyclic derivative and use thereof
DE102008018675A1 (de) 2008-04-14 2009-10-15 Bayer Schering Pharma Aktiengesellschaft Oxo-heterocyclisch substituierte Carbonsäure-Derivate und ihre Verwendung
WO2010015653A1 (en) 2008-08-07 2010-02-11 Smithkline Beecham Corporation Pyrimidine derivatives as activators of soluble guanylate cyclase
EP2401265B1 (en) * 2009-02-26 2016-09-14 Merck Sharp & Dohme Corp. Derivatives of 1-pyri(mid)in-2-yl-pyrazole-4-carboxylic acid which are useful for therapy or prophylaxis of cardiovascular diseases
DE102009012314A1 (de) 2009-03-09 2010-09-16 Bayer Schering Pharma Aktiengesellschaft Oxo-heterocyclisch substituierte Alkylcarbonsäuren und ihre Verwendung
DE102009046115A1 (de) 2009-10-28 2011-09-08 Bayer Schering Pharma Aktiengesellschaft Substituierte 3-Phenylpropansäuren und ihre Verwendung
WO2011095553A1 (en) 2010-02-05 2011-08-11 Bayer Schering Pharma Aktiengesellschaft Sgc stimulators or sgc activators in combination with pde5 inhbitors for the treatment of erectile dysfunction
DK2531187T3 (en) 2010-02-05 2015-11-09 Adverio Pharma Gmbh sGC stimulators OR sGC activators alone and in combination with PDE5 inhibitors for the treatment of cystic fibrosis
MA34249B1 (fr) 2010-05-26 2013-05-02 Bayer Ip Gmbh Utilisation de stimulateurs de la sgc, d'activateurs de la sgc, seuls et en association avec des inhibiteurs de la pde5 en vue du traitement de la sclérodermie systémique
US20130158028A1 (en) 2010-06-25 2013-06-20 Bayer Intellectual Property Gmbh Use of stimulators and activators of soluble guanylate cyclase for treating sickle-cell anemia and conserving blood substitutes
US8895583B2 (en) 2010-10-28 2014-11-25 Merck Sharp & Dohme Corp. Soluble guanylate cyclase activators
ES2544532T3 (es) 2010-12-07 2015-09-01 Bayer Intellectual Property Gmbh Ácidos 1-bencilcicloalquilcarboxílicos sustituidos y su uso
EP2683710B1 (en) 2011-03-10 2017-07-19 Boehringer Ingelheim International GmbH Soluble guanylate cyclase activators
DE102011007272A1 (de) 2011-04-13 2012-10-18 Bayer Pharma Aktiengesellschaft Verzweigte 3-Phenylpropionsäure-Derivate und ihre Verwendung
JP5826393B2 (ja) 2011-08-12 2015-12-02 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 可溶性グアニル酸シクラーゼ活性化因子
EP2594270A3 (en) 2011-11-18 2013-07-31 BIP Patents The use of sGC stimulators, sGC activators, alone and combinations with PDE5 inhibitors for the treatment of systemic sclerosis (SSc)
KR101692707B1 (ko) 2012-09-07 2017-01-04 베링거 인겔하임 인터내셔날 게엠베하 가용성 구아닐레이트 사이클라제 활성제로서의 알콕시 피라졸
JP5565645B1 (ja) 2012-10-09 2014-08-06 Ｄｉｃ株式会社 バンプクッション
US10265314B2 (en) 2013-07-25 2019-04-23 Bayer Pharma Aktiengesellschaft SGC stimulators in combination with additional treatment for the therapy of cystic fibrosis
RU2016112542A (ru) 2013-09-05 2017-10-06 Глэксосмитклайн Интеллекчуал Проперти Дивелопмент Лимитед Новые активаторы растворимой гуанилатциклазы и их применение
WO2015095515A1 (en) 2013-12-20 2015-06-25 Novartis Ag Sgc activators for the treatment of glaucoma
TW201625601A (zh) 2014-07-02 2016-07-16 諾華公司 噻吩－２－基－吡啶－２－基－１ｈ－吡唑－４－羧酸衍生物及其作為可溶性鳥苷酸環化酶活化劑之用途
TW201625586A (zh) 2014-07-02 2016-07-16 諾華公司 環己烯－１－基－吡啶－２－基－１ｈ－吡唑－４－羧酸衍生物及其作為可溶性鳥苷酸環化酶活化劑之用途
TW201625584A (zh) 2014-07-02 2016-07-16 諾華公司 茚滿及吲哚啉衍生物及其作為可溶性鳥苷酸環化酶活化劑之用途

Also Published As

Publication number Publication date
PE20170323A1 (es) 2017-04-21
EA201692542A1 (ru) 2017-04-28
ECSP17007208A (es) 2018-09-30
EA030634B1 (ru) 2018-09-28
MX2016017325A (es) 2017-05-01
AU2015283617B2 (en) 2017-10-05
PH12016502539A1 (en) 2017-04-10
CU20160192A7 (es) 2017-04-05
CO2017000222A2 (es) 2017-05-19
AP2016009609A0 (en) 2016-12-31
US10208018B2 (en) 2019-02-19
CL2016003329A1 (es) 2017-06-09
JP2017519835A (ja) 2017-07-20
US20170197940A1 (en) 2017-07-13
WO2016001875A1 (en) 2016-01-07
ES2732758T3 (es) 2019-11-25
GT201600269A (es) 2018-12-18
EP3164395B1 (en) 2019-03-27
KR20170021345A (ko) 2017-02-27
US10550102B2 (en) 2020-02-04
CN106470985A (zh) 2017-03-01
AU2015283617A1 (en) 2017-01-12
EP3164395A1 (en) 2017-05-10
TW201625584A (zh) 2016-07-16
US20190119254A1 (en) 2019-04-25
BR112016030733A2 (pt) 2017-08-22
SG11201610226SA (en) 2017-01-27
CA2953885A1 (en) 2016-01-07
TN2016000556A1 (en) 2018-04-04
CR20170003A (es) 2017-03-10
SV2016005351A (es) 2018-08-20

Similar Documents

Publication Publication Date Title
IL249406A0 (en) The history of indane and indoline and their use as soluble guanylate cyclase inhibitors
EP3152214A4 (en) Imidazo-pyrazine derivatives useful as soluble guanylate cyclase activators
ZA201703802B (en) Hydroxyalkyl-substituted phenyltriazole derivatives and uses thereof
PT3215147T (pt) Compostos de norcetamina neuroatenuante e métodos
IL247836B (en) 1, 3-benzodioxole derivatives, preparations containing them and their uses
EP3079700A4 (en) Soluble guanylate cyclase activators
EP3079701A4 (en) Soluble guanylate cyclase activators
EP3099171A4 (en) Dihydropteridinone derivatives and uses thereof
ZA201701835B (en) Novel soluble guanylate cyclase activators and their use
ZA201703768B (en) Fgf21 derivatives and uses thereof
IL252757A0 (en) A work bench and related accessories
EP3154972A4 (en) Azamophinan derivatives and use thereof
PL3229976T3 (pl) Wodna dyspersja poliuretanopolimocznikowa i wodny lakier bazowy zawierający tę dyspersję
EP3310782A4 (en) Imidazo-pyrazinyl derivatives useful as soluble guanylate cyclase activators
EP3303342A4 (en) Imidazo-pyrazinyl derivatives useful as soluble guanylate cyclase activators
EP3177147A4 (en) Dihydropteridinone derivatives and uses thereof
PL3166945T3 (pl) Nowe pochodne triazolopirymidynonu lub triazolopirydynonu i ich zastosowanie
IL259934A (en) Indane derivatives and the use thereof as soluble guanylate cyclase activators
PT3157912T (pt) Composições parasiticidas compreendendo derivados de indole, seus métodos e suas utilizações
IL261645A (en) History of dioxo-hexahydroisoindolyl and their use as cyclophilin inhibitors
PT3109242T (pt) Derivados de taxano solúveis em água e utilizações
IL249122A0 (en) History of imidazole- or 4,2,1-triazole and their use
PL3386988T3 (pl) Nowe pochodne dihydropiranopirymidynonu i ich zastosowanie
EP3227293A4 (en) 6.7-cyclicmorphinan derivatives and use thereof
HK1233641A1 (en) Indane and indoline derivatives and the use thereof as soluble guanylate cyclase activators